Dianthus Therapeutics Inc
DNTH
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.44B
Close$
$-3.07
103.5% downside
Current Fair Value
103.5% downsideOvervalued by 103.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.44 Billion |
|---|---|
| Enterprise Value | $2.82 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.2 |
| Beta | 0.07 |
| Outstanding Shares | 48,032,742 |
Return
| Return on Equity | -0.94% |
|---|---|
| Return on Assets | -0.91% |
| Return on Invested Capital | -15.84% |
Valuation & Multiples
| P/E Ratio | -749.91 |
|---|---|
| PEG | -1954.48 |
| Price to Sales | - |
| Price to Book Ratio | 3.49 |
| Enterprise Value to Revenue | 3229.25 |
| Enterprise Value to EBIT | -14.72 |
| Enterprise Value to Net Income | -249 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-1.10
Average shareholder expectationRevenue Estimate
$403,615
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.85
Average shareholder expectationRevenue Estimate
$297,182
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.1048▼ 57.04% |
|---|---|
| Total Calls | 231,800▲ 1094.85% |
| Total Puts | 256,100▲ 688.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 164.38%▲ 34.41% |
|---|---|
| Total Invested | $5.17B▲ 155.60% |
| Investors Holding | 250▲ 81.00% |
ESG Score
No data
About Dianthus Therapeutics Inc
81 employees
CEO: Jason Gardner magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused on key areas of trans...